Table 1. Characteristics of the study participants.
| Characteristic | All survivors (n=123) |
|---|---|
| Age at TBI, y, median (range) | 11.8 (1.6, 21.9) |
| Age at last followup, y, median (range) | 20.1 (4.0, 41.3) |
| Follow-up since TBI, y, median (range) | 8.0 (1.01, 24.6) |
| Sex, no. (%) | |
| Male | 77 (62.6) |
| Female | 46 (37.3) |
| Race, no. (%) | |
| White, non-Hispanic | 96 (78.0) |
| Other | 23 (18.6) |
| No response | 4 (0.03) |
| TBI dose (cGy), no. (%) | |
| Range | 12–15 Gy |
| ≤ 1410 | 54 (43.9) |
| > 1410 | 69 (56.1) |
| Primary diagnosis, no. (%) | |
| ALL/NHL | 77 (62.6) |
| AML/CML | 46 (37.4) |
| Pre-transplant therapy, no. (%) | |
| Anthracyclines | 115 (93.5) |
| Glucocorticoids* | 100 (81.3) |
| Cranial radiotherapy | 38 (30.9) |
| Pre-transplant BMI, no. (%) | |
| Obese | 20 (16.3) |
| Non-obese | 103 (83.7) |
| HCT type, no. (%) | |
| Autologous | 5 (4.1) |
| Allogeneic | 118 (95.9) |
| Graft source, no. (%) | |
| Bone marrow (BM) | 86 (69.9) |
| Peripheral blood stem cells (PBSC) | 27 (21.9) |
| Cord blood | 8 (6.5) |
| BM + Cord | 1 (0.8) |
| BM + PBSC | 1 (0.8) |
| Donor source, allogeneic transplants only, no. (%) | |
| Related | 59 (50.0) |
| Unrelated | 59 (50.0) |
| GVHD Prophylaxis**, allogeneic transplants only, no. (%) | |
| T-cell depletion | 77 (65.3) |
| Cyclosporine | 35 (29.7) |
| Methotrexate | 28 (23.7) |
| Mycophenolate mofetil | 8 (6.7) |
| Corticosteroids | 6 (5.2) |
| Tacrolimus | 5 (4.3) |
| Sirolimus | 1 (0.9) |
| Acute GVHD, allogeneic transplants only, no. (%) | |
| Grade I or none | 104 (88.1) |
| Grade II-IV | 14 (11.8) |
| Chronic GVHD, allogeneic transplants only, no. (%) | |
| No | 107 (90.7) |
| Yes | 11 (9.3) |
Abbreviations: y indicates years; HCT, hematopoietic stem cell transplant; TBI, total body irradiation; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; and GVHD, graft-versus-host disease.
*
Refers to glucocorticoids used for upfront chemotherapy;
**
Numbers do not sum to 100 percent since most allogeneic HCT recipients received more than one agent for GVHD prophylaxis